2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2138

Safety and Efficacy Results of a Phase 2, Double-Blind, Placebo-Controlled Clinical Study of Duvelisib with Background Methotrexate (MTX) in Adults with Moderate-to-Severe Rheumatoid Arthritis (RA)
Abstract Number: 3221

Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus
Abstract Number: 833

Safety and Immunogenicity of Pneumococcal Vaccine in Patients with Systemic Sclerosis and Healthy Controls
Abstract Number: 1839

Safety and Immunogenicity of Quadrivalent Human Papilloma Virus (qHPV) Vaccine (Gardasil®) in Systemic Lupus Erythematous (SLE), Phase I Trial Completion
Abstract Number: 1076

Safety and Tolerability of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease
Abstract Number: 3134

Safety and Tolerability of Pirfenidone in Patients with Systemic Sclerosis Interstitial Lung Disease
Abstract Number: 2887

Safety and Tolerability of Secukinumab in Patients with Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials
Abstract Number: 971

Safety and Tolerability of Subcutaneous Sarilumab Compared to Intravenous Tocilizumab in Patients with RA
Abstract Number: 347

Safety Observations with 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab during the Pivotal 3-Year Trial and Subjects Who Crossed over to Denosumab during the Extension
Abstract Number: 1603

Safety of Biologic and Non-Biologic Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Veterans with Rheumatoid Arthritis and Chronic Hepatitis C Infection
Abstract Number: 2311

Safety of Pregabalin for Treatment of Fibromyalgia Is Comparable Between Subjects with Moderate or Severe Baseline Widespread Pain
Abstract Number: 608

Safety of Surgery in Patients with Rheumatoid Arthritis Treated By Abatacept: Data from the French Orencia in Rheumatoid Arthritis (ORA) Registry
Abstract Number: 2425

Safety of Tocilizumab in Young Adults with Juvenile Idiopathic Arthritis (JIA)
Abstract Number: 1520

Safety, Clinical and Immunologic Effectiveness of the Live Zoster Vaccine Administered to Patients Receiving Anti-TNF Biologics
Abstract Number: 312

Safety, Efficacy and Biomarker Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].